Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
Pharmacogenomics and Personalized Medicine
|
December 11, 2012
ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics
Daniel T Barratt, Janet K Coller, Richard Hallinan, et al.
Basic & Clinical Pharmacology & Toxicology
|
February 14, 2014
Pharmacokinetic-pharmacodynamic modelling of the analgesic and antihyperalgesic effects of morphine after intravenous infusion in human volunteers
Pernille Ravn, David J R Foster, Mads Kreilgaard, et al.
Therapeutic Advances in Musculoskeletal Disease
|
April 29, 2021
Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a <i>post hoc</i> multicohort analysis
Ahmad Y Abuhelwa, David J R Foster, Arkady Manning-Bennett, et al.
Basic & Clinical Pharmacology & Toxicology
|
August 29, 2014
Pharmacodynamic modelling of placebo and buprenorphine effects on event-related potentials in experimental pain
Rasmus V Juul, David J R Foster, Richard N Upton, et al.
Journal of Clinical Pharmacology
|
April 29, 2008
Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model
Camilla Staahl, Richard Upton, David J R Foster, et al.
Basic & Clinical Pharmacology & Toxicology
|
July 5, 2008
Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers
Mette L Jensen, Per Sjøgren, Richard N Upton, et al.
Therapeutic Advances in Musculoskeletal Disease
|
July 28, 2022
The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - a pooled analysis of five randomised controlled trials
Arkady T Manning-Bennett, Ashley M Hopkins, Michael J Sorich, et al.
The AAPS Journal
|
January 29, 2020
Demonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis
Asbjørn Nøhr-Nielsen, Theis Lange, Julie Lyng Forman, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
March 7, 2016
Modelling the PKPD of oxycodone in experimental pain - Impact of opioid receptor polymorphisms
Rasmus Olsen, David J R Foster, Richard N Upton, et al.
Basic & Clinical Pharmacology & Toxicology
|
October 10, 2019
Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers
Louise Ladebo, David J R Foster, Ahmad Y Abuhelwa, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
Pharmacogenomics and Personalized Medicine
|
December 11, 2012
ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics
Daniel T Barratt, Janet K Coller, Richard Hallinan, et al.
Basic & Clinical Pharmacology & Toxicology
|
February 14, 2014
Pharmacokinetic-pharmacodynamic modelling of the analgesic and antihyperalgesic effects of morphine after intravenous infusion in human volunteers
Pernille Ravn, David J R Foster, Mads Kreilgaard, et al.
Therapeutic Advances in Musculoskeletal Disease
|
April 29, 2021
Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a <i>post hoc</i> multicohort analysis
Ahmad Y Abuhelwa, David J R Foster, Arkady Manning-Bennett, et al.
Basic & Clinical Pharmacology & Toxicology
|
August 29, 2014
Pharmacodynamic modelling of placebo and buprenorphine effects on event-related potentials in experimental pain
Rasmus V Juul, David J R Foster, Richard N Upton, et al.
Journal of Clinical Pharmacology
|
April 29, 2008
Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model
Camilla Staahl, Richard Upton, David J R Foster, et al.
Basic & Clinical Pharmacology & Toxicology
|
July 5, 2008
Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers
Mette L Jensen, Per Sjøgren, Richard N Upton, et al.
Therapeutic Advances in Musculoskeletal Disease
|
July 28, 2022
The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - a pooled analysis of five randomised controlled trials
Arkady T Manning-Bennett, Ashley M Hopkins, Michael J Sorich, et al.
The AAPS Journal
|
January 29, 2020
Demonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis
Asbjørn Nøhr-Nielsen, Theis Lange, Julie Lyng Forman, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
March 7, 2016
Modelling the PKPD of oxycodone in experimental pain - Impact of opioid receptor polymorphisms
Rasmus Olsen, David J R Foster, Richard N Upton, et al.
Basic & Clinical Pharmacology & Toxicology
|
October 10, 2019
Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers
Louise Ladebo, David J R Foster, Ahmad Y Abuhelwa, et al.
Page
of 6